Landmark BioVentures

Year Founded

2021

Ownership

Private

Employees

~10

Stage

Phase 1

Modalities

Small molecule

Landmark BioVentures General Information

Lead program DHN198 showed favorable safety profile and early signs of disease stabilization in Phase 1 trials

Contact Information

Website

Primary Industry

Biotech

Corporate Office

Basel,
Switzerland

Drug Pipeline

DHN198

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Landmark BioVentures's pipeline data

Key Partnerships

OM Pharma

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Landmark BioVentures Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Landmark BioVentures's complete valuation and funding history, request access »